Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb;36(1):72-80.
doi: 10.1111/fcp.12723. Epub 2021 Sep 13.

Orexin receptors: Targets and applications

Affiliations
Review

Orexin receptors: Targets and applications

Subhiksha Subramanian et al. Fundam Clin Pharmacol. 2022 Feb.

Abstract

Over the years, elucidating targets from the neural circuits that can be used to treat disorders pertaining to the nervous system and extending their scope to other systems have always proved interesting to researchers. The role of various peptides and neurotransmitters has been elucidated and is being developed as therapeutic targets. Out of these, orexins are neuropeptides produced in the hypothalamus that stimulate a specific type of G-Protein coupled receptors (GPCR) called orexin receptors and bring about various physiological and pathological roles. Orexin receptors are of interest not only because of their wide applications such as insomnia, obesity, and inflammatory disorders but also because of their contribution to promising aspects of drug discovery such as optogenetics and their tremendous growth from the stage of being orphans to orexins. This review will discuss in detail the structure of orexin receptors, their physiological role, and various applications in disease states adding a note on agonists and antagonists and finally summarizing the recent drug approvals in the field.

Keywords: agonist; antagonist; orexin system; physiological role.

PubMed Disclaimer

References

REFERENCES

    1. Scammell TE, Winrow CJ. Orexin receptors: Pharmacology and therapeutic opportunities. Annu Rev Pharmacol. 2011;51(1):243-266.
    1. Langmead CJ. From orphans to orexins: An arousing fifteen years. Br J Pharmacol. 2014;171(2):281-282.
    1. Li J, Hu Z, de Lecea L. The hypocretins/orexins: Integrators of multiple physiological functions. Br J Pharmacol. 2014;171(2):332-350.
    1. Kukkonen JP, Leonard CS. Orexin/hypocretin receptor signaling cascades. Br J Pharmacol. 2014;171(2):314-331.
    1. Leonard CS, Kukkonen JP. Orexin/hypocretin receptor signaling: A functional perspective. Br J Pharmacol. 2014;171(2):294-313.

LinkOut - more resources